Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.
Saved in:
| Title: | Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. |
|---|---|
| Authors: | Gordon SC; Division of Hepatology, Henry Ford Health, Wayne State University School of Medicine, Detroit, Michigan, USA.; College of Medicine, Michigan State University, East Lansing, Michigan, USA., Villamil A; The Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Jacobson IM; NYU Grossman School of Medicine, New York, New York, USA., Lawitz EJ; Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, USA., Younes Z; Gastro One, Germantown, Tennessee, USA., Silveira MG; Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Bowlus CL; Division of Gastroenterology and Hepatology, University of California, Davis School of Medicine, Sacramento, California, USA., Drenth JPH; Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands., Vierling JM; Section of Gastroenterology and Hepatology and Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA., Morgera U; Internal Medicine, Outpatient Clinic, Charité, Universitätsmedizin Berlin, Berlin, Germany., Vasura A; Department of Internal Medicine and Cardiology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic., Dalekos G; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece., Galli A; Gastroenterologia Clinica, Azienda Ospedaliero-Universitaria Careggi, Florence (Firenze), Italy., Rabinovitz M; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Heo J; Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Nevens F; Hepatology and Liver Transplantation, University Hospitals KU Leuven, Leuven, Belgium.; Center of European Reference Network (ERN) RARE-LIVER, Leuven, Belgium., Levy C; Division of Digestive Health and Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida, USA.; Schiff Center for Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida, USA., Zhou Y; Gilead Sciences, Inc., Foster City, California, USA., Carroll S; Gilead Sciences, Inc., Foster City, California, USA., Crittenden DB; Gilead Sciences, Inc., Foster City, California, USA. |
| Source: | Hepatology communications [Hepatol Commun] 2026 Apr 13; Vol. 10 (5). Date of Electronic Publication: 2026 Apr 13 (Print Publication: 2026). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III |
| Journal Info: | Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
